Soteria® is a revolutionary new technology that allows patients to take biopharmaceutical drugs, including monoclonal antibodies, as a simple and safe tablet or capsule.


Phloral® is a cutting-edge technology for precise and consistent delivery to the colon. It exploits changes in gastrointestinal pH in combination with the enzymatic activity of the microbiota as independent but complementary release mechanisms to guarantee site-specific release.

Featured News

Intract’s founder and CSO awarded £10 million EPSRC grant in collaboration with Cambridge, Imperial, Birmingham and Glasgow Universities

Intract’s Phloral® technology rated among top emerging drug delivery technologies

Intract Pharma has moved